Missed their end point in the Phase IIB study, but still think there is value here. Selling off today as a result, but company looking at numbers, more to come I believe with a couple other drugs still in the pipeline. Institutional ownership is high on this one also, over 80 %. Big boys don't look to lose their $. Could be oversold, may be a buying opportunity here at today's prices./ok2
Theravance Biopharma, Inc. engages in the research and development activities focusing on the diseases of the lung and gastrointestinal tract, and infectious diseases, as well as on the acute care setting markets. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. The company's TD-4208, an investigational long-acting muscarinic antagonist, which has completed Phase IIb study for the treatment of chronic obstructive pulmonary disease; and Axelopran, an investigational, once-daily, and oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trial for opioid-induced constipation. It also offers Velusetrag, an oral and investigational medicine, which has completed first Phase II study for gastrointestinal motility disorders. The company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol; the MABA program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. is incorporated in 2013 and is based in George Town, the Cayman Islands.
## source: finance.yahoo.com
Fri, 28 Aug 2015 20:40:14 GMT ~ THERAVANCE BIOPHARMA, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements
Thu, 27 Aug 2015 20:54:01 GMT ~ Theravance Biopharma to Present at the Baird 2015 Healthcare Conference
[at noodls] - August 27, 2015 DUBLIN, IRELAND -- (Marketwired) -- 08/27/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer and other members ...
Thu, 27 Aug 2015 20:30:00 GMT ~ Theravance Biopharma to Present at the Baird 2015 Healthcare Conference
[Marketwired] - Theravance Biopharma, Inc. announced today that Rick E Winningham, Chairman and Chief Executive Officer and other members of the management team will participate in a fireside chat at the Baird 2015 Healthcare ...